Impact of Radioimmunoscintigraphy on the Management of Colorectal and Ovarian Cancer Patients: A Retrospective Study

References

• Miller A B. Cancer screening (Section 4). Principles and Practice of Oncology, 3rd ed., V T DeVita, S Hellman, S A Rosenberg. JB Lipincott, New York 1989; 478–485
   Google Scholar
• White R I, Jr. Interventional radiology: Reflections and expectations, The 1985 Eugene P. Pendergrass New Horizons Lecture. Radiology 1987; 162: 593–600
   PubMed Web of Science ®Google Scholar
• Claman H N. The biology of the immune response. JAMA 1992; 268: 2790–2796
   PubMed Web of Science ®Google Scholar
• Pressman D, Korngold L. The in vivo localization of anti-Wagner osteogenic sarcoma with labeled antibodies. Cancer 1953; 6: 7619–7623
   Google Scholar
• Reisfeld R A, Cheresh D A. Human tumor antigens. Adv Immunol 1987; 40: 323–377
   PubMed Web of Science ®Google Scholar
• Patt Y Z, Lamki L M, Haynie T P, et al. Improved tumor localization with increasing dose of Indium-Ill-labeled anti-carcinoem-bryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer. J Clin Oncol 1988; 6: 1220–1230
   PubMed Web of Science ®Google Scholar
• Britton K E, Buraggi G L, Bares R, et al. A brief guide to the practice of radioimmunoscintigraphy in cancer. Int J Biol Markers 1989; 4: 106–118
   PubMedGoogle Scholar
• Bares R, Fass J, Weiller G, et al. Planar vs SPECT radioimmunoscintigraphy, clinical experience with Tc-99m, In- 111 and 1–131 labelled monoclonal antibodies against CEA and/or Ca 19.9. Nuklearmed 1987; 4: 24–25
   Google Scholar
• Abdel-Nabi H H, Schwartz A N, Goldfogel G, et al. Colorectal tumors: scintigraphy with ln-111 anti-CEA monoclonal antibody and correlation with surgical, histopathologic, and immunohisto-chemical findings. Radiology 1988; 166: 747–752
   PubMed Web of Science ®Google Scholar
• Berche C, Mach J P, Lumbroso J D, et al. Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabeled monoclonal antibodies against car-cinoembryonic antigen. Br Med J 1982; 285: 1447–1451
   PubMed Web of Science ®Google Scholar
• Kramer E L, Sanger J J, Walsh C, et al. Contribution of SPECT to imaging gastrointestinal adenocarcinoma with In-111-labeled anti-CEA monoclonal antibody. Am J Roentgenol 1988; 151: 697–703
   PubMed Web of Science ®Google Scholar
• Loats H. CT and SPECT image registration and fusion for spatial localization of metastatic processes using radiolabeled mono-ctonals. J Nucl Med 1993; 34: 562–566
   PubMed Web of Science ®Google Scholar
• Rodwell J D, Alvarez V L, Less C, et al. Site-specific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations. Proc Natl Acad Sci USA 1986; 83: 2632–2636
   PubMed Web of Science ®Google Scholar
• Winzelbewrg G G, Grossman S J, Rizk S, et al. Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer. Cancer 1992; 69: 1656–1663
   PubMedGoogle Scholar
• Collier B D, Abdel Nabi H, Doerr R J, et al. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 1992; 185: 179–186
   PubMed Web of Science ®Google Scholar
• Blend M J. Current status of tumor imaging with monoclonal antibodies. Compr Ther 1991; 17: 5–11
   PubMedGoogle Scholar
• Blend M J. Monoclonal antibody imaging in patients with stage II melanoma and low grade B-cell lymphoma using a Tc-99m label. Rev Espan Med Nucl 1992; 11: 41–43
   Google Scholar
• Maroli A N, Maguire R T, Pascucci V L, Pruch J M. Clinical experience with indium-111-labeled satumomab pendetide (Onco-Scint CR/OV). Nuclear Medicine: Principles and Practice, R E Henkin. Mosby Year Book, Chicago 1995; 581–593
   Google Scholar
• Goldenberg D M, Larson S M. Radioimmunodetection in cancer identification. J Nucl Med 1992; 33: 803–814
   PubMed Web of Science ®Google Scholar
• Goldenberg D M, Kim E, Deland F, et al. Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res 1980; 40: 2984–2992
   PubMed Web of Science ®Google Scholar
• Abdel-Nabi H H. Antibody imaging in colon cancer. Appl Radiol 1992; 21: 59–64
   Google Scholar
• van Nagell J R, Jr, Kim E E, Casper S, et al. Radioimmunodetection of primary and metastatic ovarian cancer using radiolabeled antibodies to carcinoembryonic antigen. Cancer Res 1980; 40: 502–506
   PubMed Web of Science ®Google Scholar
• Lastoria S, D'Amico P, Mansi L, et al. A prospective imaging study of 1–131-B72.3 monoclonal antibody in patients with epithelial ovarian cancer. Preliminary report. Nucl Med Commun 1988; 9: 347–356
   PubMed Web of Science ®Google Scholar
• Chatal J F, Fumoleau P, Saccavini J C, et al. Immunoscintigraphy of recurrences of gynecologic carcinomas. J Nucl Med 1987; 28: 1807–1819
   PubMed Web of Science ®Google Scholar
• Barzen G, Mayr A C, Langer M, et al. Radioimmunoscintigraphy of ovarian cancer with 1–131 -labeled OC-125 antibody fragments. Eur J Nucl Med 1987; 15: 42–48
   Google Scholar
• Epenetos A A, Lavender J P, Kenemans P, et al. Early results of the monoclonal antibody OV-TL3 in specific detection of ovarian cancer. J Clin Oncol 1987; 5: 160
   PubMed Web of Science ®Google Scholar
• Massuger L FAG, Kenemans P, Claessens R AMJ, et al. Immunoscintigraphy of ovarian cancer with indium-111 labeled OV-TLE F(ab')2 monoclonal antibody. J Nucl Med 1990; 31: 1802–1910
   PubMed Web of Science ®Google Scholar
• Surwit E A, Childers J M, Krag D N, et al. Clinical assessment of In-11 l-CYT-103 immunosccintigraphy in ovarian cancer. Gynecol Oncol 1993; 48: 285–292
   PubMed Web of Science ®Google Scholar
• Nudlemann L I, Cabot R, Benjamin I S, et al. Hepatic reaction for secondary tumors. Cancer Surv 1989; 8: 33–47
   PubMedGoogle Scholar
• Pickren N J, Tsukaday P, Lane W W. Liver metastases: analysis of autopsy data. Liver Metastases, L Weiss, H A Gilver. GK Hall, Boston 1982; 2–18
   Google Scholar
• Markowitz A, Saleemi K, Freeman L M. Role of In-111 labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma. Clin Nucl Med 1993; 18: 685–699
   PubMed Web of Science ®Google Scholar
• Galandiuk S. Immunoscintigraphy in the surgical management of colorectal cancer. J Nucl Med 1993; 34: 541–544
   PubMed Web of Science ®Google Scholar
• Reynolds J C, Del Vecchio S, Sakahara H, et al. Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications. Nucl Med Biol Int J Radiat Appl Instrum (Part B) 1989; 16: 121–125
   PubMedGoogle Scholar
• LoBuglio A F, Wheeler R H, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 1989; 86: 4220–4224
   PubMed Web of Science ®Google Scholar
• Pinsky C M, Goldenberg D M, Wlodkowski T J, et al. Detection of occult metastases of colorectal cancer by the use of anti-CEA Fab' fragments labeled with Tc-99m. J Nucl Med 1991; 32: 1053
   Google Scholar
• Lamki L M. Radioimmunoscintigraphy of cancer: Problems, pitfalls, and prospects. Nucl Med Ann 1990; 113–150
   Google Scholar
• Rosenblum M G, Lamki L M, Murray J L, et al. Interferon induced changes in pharmacokinetics and tumor uptake of In-111 labeled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst 1988; 80: 160–165
   PubMed Web of Science ®Google Scholar
• Greiner J W, Guadagni F, Noguchi P, et al. Recombinant interferon enhances monoclonal antibody targeting of carcinoma lesions in vivo. Science 1987; 235: 895–898
   PubMed Web of Science ®Google Scholar
• Greiner J W, Hand P H, Noguchi P, et al. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte a-interferon treatment. Cancer Res 1984; 44: 3208–3214
   PubMed Web of Science ®Google Scholar
• Blumenthal R D, Sharkey R M, Snyder D, et al. Reduction of ra-dioantibody-induced myelotoxicity in hamsters by recombinant interleukin-1. Cancer Res 1988; 48: 5403–5406
   PubMed Web of Science ®Google Scholar
• Leichner P K, Yang N C, Frankel T L, et al. Dosimetry and treatment planning for Y-90 labeled antiferritin in hepatoma. Int J Radiat Oncol Biol Phys 1988; 14: 1033–1042
   PubMed Web of Science ®Google Scholar
• Steis R G, Carrasquillo J A, McCabe R, et al. Toxicity, immunoge-nicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Oncol 1990; 8: 476–490
   PubMed Web of Science ®Google Scholar
• Brand E, Hohfsfield R, Bunn P, et al. Monoclonal antibody imaging of ovarian cancer with intraperitoneal indium-111 CYT-103 antibody to TAG-72.3 antigen. Gynecol Oncol 1990; 36: 285–286
   Google Scholar
• Abdel-Nabi H, Doerr R J. Locatization of colorectal carcinoma with a combination of In-111 CYT-111 and In-1 II CYT-372 monoclonal antibodies. J Nucl Med 1994; 35: 1IP
   Google Scholar
• Alvarez V L, Radcliff R D, Coughlin D J, . Molecular recognition units and radioimaging of human disease. Diagnostic Uses of Radiolabeled Monoclonal Antibodies, M K Haseman, et al. American College of Nuclear Physicians, Washington, DC 1992; 111–128
   Google Scholar
• Fawwaz R A, Wang T S, Srivastava S, et al. Potential of palladium-109 labeled antimelanoma monoclonal antibody for tumor therapy. J Nucl Med 1984; 25: 796–799
   PubMed Web of Science ®Google Scholar
• Brady L W, Markoe A M, Woo D V. The present and future role of monoclonal antibodies in the management of cancer. Rad Ther Oncol. 1990; 24: 247–259
   PubMedGoogle Scholar
• Collier B D, Foley W D. Current imaging strategies for colorectal cancer. Nucl Med 1993; 34: 537–540
   Web of Science ®Google Scholar